News related to Viread (Tenofovir Disoproxil) and/or conditions it is approved for
Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Source: Medscape HIV/AIDS Headlines [2017.09.26] A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial. Reuters Health Information
|